Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Levact (bendamustine) - Important Safety Information from Mundipharma Pharmaceuticals Ltd. as approved by the HPRA
Notice type:
3rd Party Publications
Date:
12/06/2017
Problem Or Issue:
Important Safety Information communication from Mundipharma Pharmaceuticals Ltd. on increased mortality, serious & fatal infections, reactivation of Hepatitis B, prolonged lympocytopenia and low CD4-positive T-cell counts observed in recent clinical studies with Levact (bendamustine).
Important Safety Information - Levact (bendamustine)
« Back
Date Printed: 25/04/2024